Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of nausea and vomiting in patients receiving emetogenic chemotherapy.
• Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures.
• Radiotherapy‑induced nausea and vomiting: helps control nausea associated with radiation treatment.

• Ondansetron acts as a selective antagonist of serotonin 5‑HT3 receptors located in the chemoreceptor trigger zone of the brain and on vagal afferents in the gastrointestinal tract. By blocking these receptors, it inhibits serotonin‑mediated signaling that initiates the vomiting reflex, thereby reducing nausea and vomiting triggered by chemotherapy, radiation, or surgery.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Constipation: reduced bowel movements or hard stools.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: feeling unusually tired or weak.
• Injection‑site reaction: erythema, pain or swelling at the IV site.
• Diarrhoea: loose stools occurring after administration.

Serious or Rare Side Effects

• QT interval prolongation: potential cardiac rhythm disturbance.
• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents.
• Cardiac arrhythmia: irregular heartbeats that may be life‑threatening.
• Hypotension: sudden drop in blood pressure.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Before using Ondansetron Kabi, consider the following precautions:

• Cardiac risk assessment: evaluate baseline ECG and electrolyte status to mitigate QT‑prolongation risk.
• Concomitant QT‑prolonging drugs: avoid or monitor closely when used with other agents that affect cardiac repolarisation.
• Hepatic impairment: adjust use in patients with severe liver disease as metabolism may be reduced.
• Pregnancy and lactation: use only if the potential benefit outweighs potential risk; data are limited.
• Pediatric use: safety and efficacy have not been established in children for this formulation.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron Kabi may interact with several medicines. Review the following categories:

Major Interactions (Avoid)

• Other QT‑prolonging agents (e.g., quinidine, haloperidol): may increase risk of cardiac arrhythmia.
• Apomorphine: can cause severe hypotension and loss of consciousness.
• Serotonergic drugs (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.
• Carbamazepine: induces metabolism, potentially reducing ondansetron efficacy.

Moderate Interactions (Monitor Closely)

• Dexamethasone: may enhance antiemetic effect; monitor for additive side effects.
• Warfarin: possible increase in INR; check coagulation parameters.
• Anticholinergic agents: may alter gastrointestinal motility; observe clinical response.
• Other antiemetics (e.g., metoclopramide): combined use may increase side‑effect burden.